March 29, 2022
Ozempic 2.0 mg Approved in the US for the Treatment of Type 2 Diabetes
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s a 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analogue for the treatment of adults with type 2 diabetes.
